Gilead Sciences (GILD, news, chart) is trading up $1.60 to $56.64 and calls are busy after RBC analysts said it expects the company to get FDA approval for Vireas for Hepatitis B by August 11. It is one of two expected FDA approvals. The other being Astreonam lysine for cystic fibrosis, which has a PDUFA date of September 16. In the options market, players are also bullish, with 19,000 GILD calls and 5,000 puts trading on the day. The January 55 and 60 calls are the most actives. More than 4,500 have traded in each. The volume includes orders for 2,647 of the 55s traded offerside for $6.35 a contract and the same number of 60s traded bidside for $3.75. While it is possible that some of the action is closing, it seems more likely to be bull call spread trading. If so, the strategist is paying a net debit of $2.60 per spread and has the potential of making $2.40 if GILD rallies to $60 or more by January options expiration.